Ardent Health reported fourth‑quarter 2025 revenue of $1.61 billion, matching the prior‑year figure but falling short of the $1.64 billion consensus estimate. Adjusted EBITDA for the quarter was $134 million, a decline from $183 million in Q4 2024, and operating cash flow reached $223 million. Earnings per share were $0.32, missing the $0.35 estimate by $0.03.
The revenue flatness masks a 27% drop in adjusted EBITDA, driven by a 2.0% rise in adjusted admissions that was offset by a 2.4% decline in net patient service revenue per admission. The combination of higher patient volume and lower revenue per admission reflects the impact of payor denial and professional fee pressures that the company has been battling.
Full‑year 2026 guidance was set at $6.40 billion to $6.70 billion in revenue and $485 million to $535 million in adjusted EBITDA, both below analyst consensus of $6.70 billion revenue and $1.40 EPS. The guidance reflects headwinds from elevated professional fees, payor denials, Exchange disruption, and the restoration of short‑term compensation.
Marty Bonick, President and CEO, said, "I'm pleased with tangible progress from the deliberate, measurable actions we took during the fourth quarter to mitigate the payor denial and professional fee industry pressures we outlined on the third quarter earnings call." He added, "Disciplined execution and expense optimization drove solid fourth quarter adjusted EBITDA results. Our IMPACT program is building traction and resulted in significant SWB expense improvements, particularly in contract labor." Bonick also noted, "We are taking a prudent approach to establishing our 2026 adjusted EBITDA guidance of $485-$535 million." He further explained, "We enter 2026 with improving momentum from our IMPACT program, which we now expect to generate $55 million of savings this year, up from $40 million previously."
Following the release, Ardent Health shares fell 11.8%. The decline was driven primarily by the weak 2026 guidance and the missed revenue and EPS estimates, which signaled to investors that the company’s near‑term outlook remains constrained by industry headwinds.
The results underscore the company’s ongoing struggle to translate volume growth into profitability. While the IMPACT program has delivered cost savings, the headwinds from payor denials and professional fee pressures continue to erode margins. The guidance suggests management remains cautious, prioritizing margin preservation over aggressive growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.